公开(公告)号：US20050003483A1

公开(公告)日：2005-01-06

申请号：US10845391

申请日：2004-05-13

申请人： William Hildebrand ,  Heather Hickman-Miller

发明人： William Hildebrand ,  Heather Hickman-Miller

IPC分类号： A61K9/127 ,  A61K38/00 ,  A61K39/00 ,  A61K39/385 ,  A61K39/39 ,  A61K47/48 ,  C07K1/04 ,  C07K14/16 ,  C07K14/47 ,  C07K14/705 ,  C07K14/74 ,  C07K14/78 ,  C12N9/12 ,  C12N9/64 ,  C12P21/02 ,  G01N33/50 ,  C07H21/04 ,  C07K16/18

CPC分类号： G01N33/5011 ,  A61K9/1272 ,  A61K38/00 ,  A61K39/00 ,  A61K39/385 ,  A61K39/39 ,  A61K2039/55555 ,  A61K2039/605 ,  A61K2039/622 ,  C07K1/047 ,  C07K14/005 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4728 ,  C07K14/70539 ,  C07K14/70571 ,  C07K14/78 ,  C07K2319/00 ,  C07K2319/20 ,  C07K2319/21 ,  C12N9/1247 ,  C12N9/6421 ,  C12N2740/16122 ,  C12P21/02 ,  G01N33/5008 ,  G01N33/5017 ,  G01N33/505

摘要： The present invention relates generally to a methodology for the isolation, purification and identification of peptide ligands presented by MHC positive cells. In particular, the methodology of the present invention relates to the isolation, purification and identification of these peptide ligands from soluble class I and class II MHC molecules which may be from uninfected, infected, or tumorigenic cells. The methodology of the present invention broadly allows for these peptide ligands and their cognate source proteins thereof to be identified and used as markers for infected versus uninfected cells and/or tumorigenic versus nontumorigenic cells with said identification being useful for marking or targeting a cell for therapeutic treatment or priming the immune response against infected cells.

摘要翻译： 本发明一般涉及由MHC阳性细胞提供的肽配体的分离，纯化和鉴定的方法。 特别地，本发明的方法涉及从可能来自未感染，感染或致瘤细胞的可溶性I类和II类MHC分子中分离，纯化和鉴定这些肽配体。 本发明的方法广泛地允许鉴定这些肽配体及其同源来源蛋白，并将其用作感染与未感染的细胞和/或致瘤性与非致癌性细胞的标记，所述鉴定可用于标记或靶向用于治疗的细胞 治疗或引发针对感染细胞的免疫应答。

公开(公告)号：US20060034865A1

公开(公告)日：2006-02-16

申请号：US11253009

申请日：2005-10-18

申请人： William Hildebrand ,  Heather Hickman

发明人： William Hildebrand ,  Heather Hickman

IPC分类号： A61K39/00 ,  A61K9/127

CPC分类号： A61K39/385 ,  A61K9/1272 ,  A61K39/39 ,  A61K47/6911 ,  A61K2039/55555 ,  A61K2039/605 ,  A61K2039/622

摘要： An artificial antigen presenting cell includes a liposome having at least one recombinant soluble MHC-peptide complex incorporated therein. The artificial antigen presenting cell may also include at least one additional signal molecule incorporated therein for manipulating the intensity and quality of the immune response. The recombinant soluble MHC molecule is obtained by a method utilizing PCR amplification of gDNA or cDNA, and a tag is attached thereto for anchoring the recombinant soluble MHC molecule to the liposome.

公开(公告)号：US20070099183A1

公开(公告)日：2007-05-03

申请号：US11601058

申请日：2006-11-17

申请人： William Hidebrand ,  Heather Hickman

发明人： William Hidebrand ,  Heather Hickman

IPC分类号： C12Q1/70 ,  G01N33/567

CPC分类号： G01N33/6878 ,  A61K39/39 ,  A61K2039/605 ,  A61K2039/622 ,  C07K14/005 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4728 ,  C07K14/70539 ,  C07K14/70571 ,  C07K14/78 ,  C07K16/2833 ,  C07K2319/00 ,  C12N9/1247 ,  C12N9/6421 ,  C12N2740/16122 ,  G01N33/5008 ,  G01N33/502 ,  G01N33/5044 ,  G01N33/5091 ,  G01N33/569 ,  G01N33/6824 ,  G01N33/6848 ,  G01N2333/16 ,  G01N2333/70539

摘要： The present invention relates generally to a methodology for the isolation, purification and identification of peptide ligands presented by MHC positive cells. In particular, the methodology of the present invention relates to the isolation, purification and identification of these peptide ligands from soluble class I and class II MHC molecules which may be uninfected, infected, or tumorgenic. The methodology of the present invention broadly allows for these peptide ligands and their comcomittant source proteins thereof to be identified and used as markers for infected versus uninfected cells and/or tumorgenic versus nontumorgenic cells with said identification being useful for marking or targeting a cell for therapeutic treatment or priming the immune response against infected cells.

摘要翻译： 本发明一般涉及由MHC阳性细胞提供的肽配体的分离，纯化和鉴定的方法。 特别地，本发明的方法涉及从可能未感染，感染或肿瘤的可溶性I类和II类MHC分子中分离，纯化和鉴定这些肽配体。 本发明的方法广泛地允许鉴定这些肽配体及其共有的源蛋白，并将其用作感染的与未感染的细胞和/或肿瘤与非肿瘤细胞的标记，所述鉴定可用于标记或靶向用于治疗的细胞 治疗或引发针对感染细胞的免疫应答。

公开(公告)号：US20060040310A1

公开(公告)日：2006-02-23

申请号：US11257286

申请日：2005-10-24

申请人： William Hildebrand ,  Rico Buchli ,  Kiley Prilliman ,  Heather Hickman

发明人： William Hildebrand ,  Rico Buchli ,  Kiley Prilliman ,  Heather Hickman

IPC分类号： C12Q1/68 ,  G01N33/53

CPC分类号： A61K39/385 ,  A61K9/1272 ,  A61K39/39 ,  A61K2039/55555 ,  A61K2039/605 ,  A61K2039/622 ,  C07K14/005 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4728 ,  C07K14/70539 ,  C07K14/70571 ,  C07K14/78 ,  C07K2319/00 ,  C12N9/1247 ,  C12N9/6421 ,  C12N2740/16122 ,  G01N33/5008 ,  G01N33/5041 ,  G01N33/6878

摘要： The present invention relates generally to a methodology for assaying the binding of a peptide to an individual, specific, soluble HLA molecule. The peptides utilized in the method may be identified by indirect methods utilizing T lymphocytes, or by a direct method of epitope discovery described herein.